These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19784522)

  • 1. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
    Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
    Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
    Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
    J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
    Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
    Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
    J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
    Jentschke M; Soergel P; Hillemanns P
    J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
    Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
    Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
    J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test.
    Tang N; Huang S; Erickson B; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S25-8. PubMed ID: 19651365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.
    Cuzick J; Ambroisine L; Cadman L; Austin J; Ho L; Terry G; Liddle S; Dina R; McCarthy J; Buckley H; Bergeron C; Soutter WP; Lyons D; Szarewski A
    J Med Virol; 2010 Jul; 82(7):1186-91. PubMed ID: 20513082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
    Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
    J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
    Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
    J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
    Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
    J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.